Cryo-Cell International, Inc. (CCEL) has a negative trailing P/E of -12.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 45.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -8.15%, forward earnings yield 2.18%.
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -26.1 | 0.22 | -2.24 | 1.49 | - |
| 2017 | 24.6 | -0.08 | -4.55 | 2.24 | - |
| 2018 | -63.9 | 0.48 | -6.13 | 1.87 | - |
| 2019 | 27.7 | -0.08 | -9.13 | 2.00 | - |
| 2020 | 16.8 | 0.26 | -22.91 | 1.96 | - |
| 2021 | 48.4 | -1.05 | 24.08 | 3.49 | - |
| 2022 | 13.3 | 0.50 | -24.27 | 1.22 | 20.74% |
| 2023 | -4.7 | 0.01 | -4.05 | 1.42 | - |
| 2024 | 175.3 | -1.68 | -5.33 | 2.20 | 2.87% |
| 2025 | -13.2 | 0.02 | -1.73 | 1.02 | 10.06% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.16 | $23.13M | $-1.32M | -5.7% |
| 2017 | $0.30 | $25.38M | $2.32M | 9.1% |
| 2018 | $-0.11 | $29.22M | $-854.82K | -2.9% |
| 2019 | $0.27 | $31.82M | $2.29M | 7.2% |
| 2020 | $0.45 | $31.15M | $3.62M | 11.6% |
| 2021 | $0.25 | $28.88M | $2.08M | 7.2% |
| 2022 | $0.33 | $30.34M | $2.77M | 9.1% |
| 2023 | $-1.14 | $31.34M | $-9.52M | -30.4% |
| 2024 | $0.05 | $31.99M | $402.1K | 1.3% |
| 2025 | $-0.30 | $31.57M | $-2.43M | -7.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.08 | $0.08 – $0.08 | $30.3M | $30.3M – $30.3M | 1 |
| 2027 | $0.07 | $0.07 – $0.07 | $31.5M | $31.5M – $31.5M | 1 |
